Caccamo N, Barera A, Di Sano C, Meraviglia S, Ivanyi J, Hudecz F, Bosze S, Dieli F, Salerno A
Department of Biopathology, University of Palermo, 90134 Palermo, Italy.
Clin Exp Immunol. 2003 Aug;133(2):260-6. doi: 10.1046/j.1365-2249.2003.02201.x.
The identification of immunodominant and universal mycobacterial peptides could be applied to vaccine design and have an employment as diagnostic reagents. In this paper we have investigated the fine specificity, clonal composition and HLA class II restriction of CD4+ T cell clones specific for an immunodominant epitope spanning amino acids 91-110 of the 16-kDa protein of Mycobacterium tuberculosis. Twenty-one of the tested 28 clones had a Th1 profile, while seven clones had a Th0 profile. None of the clones had a Th2 profile. While the TCR AV gene usage of the clones was heterogeneous, a dominant TCR BV2 gene family was used by 18 of the 28 clones. The CDR3 regions of BV2+ T cell clones showed variation in lengths, but a putative common motif R-L/V-G/S-Y/W-E/D was detected in 13 of the 18 clones. Moreover, the last two to three residues of the putative CDR3 loops, encoded by conserved BJ sequences, could also play a role in peptide recognition. Antibody blockade and fine restriction analysis using HLA-DR homozygous antigen-presenting cells established that 16 of 18 BV2+ peptide-specific clones were DR restricted and two clones were DR-DQ and DR-DP restricted. Additionally, five of the 18 TCRBV2+ clones recognized peptide 91-110 in association with both parental and diverse HLA-DR molecules, indicating their promiscuous recognition pattern. The ability of peptide 91-110 to bind a wide range of HLA-DR molecules, and to stimulate a Th1-type interferon (IFN)-gamma response more readily, encourage the use of this peptide as a subunit vaccine component.
免疫显性和通用分枝杆菌肽的鉴定可应用于疫苗设计,并可用作诊断试剂。在本文中,我们研究了针对结核分枝杆菌16 kDa蛋白91 - 110氨基酸的免疫显性表位的CD4 + T细胞克隆的精细特异性、克隆组成和HLA II类限制性。在测试的28个克隆中,21个具有Th1型,7个具有Th0型。没有克隆具有Th2型。虽然克隆的TCR AV基因使用情况是异质的,但28个克隆中有18个使用了占主导地位的TCR BV2基因家族。BV2 + T细胞克隆的CDR3区域长度存在差异,但在18个克隆中的13个中检测到一个假定的共同基序R - L/V - G/S - Y/W - E/D。此外,由保守的BJ序列编码的假定CDR3环的最后两到三个残基也可能在肽识别中起作用。使用HLA - DR纯合抗原呈递细胞进行的抗体阻断和精细限制性分析表明,18个BV2 +肽特异性克隆中有16个受DR限制,2个克隆受DR - DQ和DR - DP限制。此外,18个TCRBV2 +克隆中有5个识别与亲本和不同HLA - DR分子相关的肽91 - 110,表明它们具有混杂的识别模式。肽91 - 110能够结合广泛的HLA - DR分子,并更易于刺激Th1型干扰素(IFN)-γ反应,这促使将该肽用作亚单位疫苗成分。